Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | THRA | P10827 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | CAPN1 | P07384 | 7/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | NAAA | Q02083 | 1/20 | 0.34 |
| ▸ | CYSLTR2 | Q9NS75 | 3/20 | 0.34 |
| ▸ | CYSLTR1 | Q9Y271 | 3/20 | 0.34 |
| ▸ | FAAH | O00519 | 2/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22800999 | 0.79 | CAPN1 (0.47) | MAPTTHRATHRBCAPN1TSHR | |
| SCHEMBL22800227 | 0.74 | CYP4F2 (0.39) | MAPTTHRATHRBTSHRHTT | |
| SCHEMBL22799768 | 0.74 | CYP4F2 (0.39) | MAPTTHRATHRBTSHRHTT | |
| SCHEMBL22800230 | 0.74 | CYP4F2 (0.39) | MAPTTHRATHRBTSHRHTT | |
| SCHEMBL22799715 | 0.73 | ALDH1A1 (0.48) | MAPTTHRBCAPN1TSHRCTSK | |
| SCHEMBL2326565 | 0.72 | CA12 (0.41) | HTTNAAACYSLTR2CYSLTR1 | |
| SCHEMBL2326571 | 0.72 | CA12 (0.41) | HTTNAAACYSLTR2CYSLTR1 | |
| SCHEMBL12984473 | 0.72 | CA2 (0.43) | TSHRHTT | |
| SCHEMBL2328069 | 0.71 | CYSLTR2 (0.41) | NAAACYSLTR2CYSLTR1 | |
| SCHEMBL2328207 | 0.71 | CA2 (0.45) | CYSLTR2CYSLTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200392157-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | Knobbe, Martens, Olson & Bear, LLP | 2020-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392157-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPNS1, CAPN2, CAPN1 | MAPT 472/4885THRA 3614/4885THRB 2737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.